Valeritas (NSDQ:VLRX) said today that it inked a deal with Aspire Capital Fund to buy $20 million of Valeritas’ common stock.
According to the deal, Aspire Capital is slated to purchase common stock at Valeritas’ request from time to time during a 30-month period at prices based on the market price at the time of each sale.
“This agreement with Aspire provides us access to capital to support our commercial operations and advancing our product pipeline,” president & CEO John Timberlake said in prepared remarks.
Get the full story at our sister site, Drug Delivery Business News.
The post Aspire Capital to acquire $20m worth of Valeritas stock appeared first on MassDevice.
from MassDevice http://ift.tt/2yqwV6G
Cap comentari:
Publica un comentari a l'entrada